Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology
Disease Category: Schizophrenia and Schizoaffective Disorders
Location: United States, IL
A 17-week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment with LY2140023 Combined with SOC to placebo Combined with SOC as the Treatment of Patients with DSM-IV-TR Schizophrenia with Prominent Negative Symptoms
The primary objective of this study is to determine if treatment with LY2140023
compared to placebo (an inactive substance), when added to a fixed dose of a standard of care (SOC) antipsychotic, will demonstrate significantly greater reduction of negative symptoms.
Patients included in this study will be concurrently receiving 1 of 4 current FDA approved antipsychotics: aripiprazole, olanzapine, risperidone, or quetiapine
Please contact Alexian Brothers for more information on participation.
Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these